13hon MSN
Novel prostate cancer treatment can reduce risk of disease progression by half, clinical trial shows
A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer ...
By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...
Stories by SWNS on MSN
Prostate cancer treatment breakthrough could boost survival rates
A breakthrough in treating an aggressive form of prostate cancer could boost survival rates, according to new research.
By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...
A novel theranostic approach that targets RET—a newly identified biomarker for neuroendocrine prostate cancer—enables ...
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...
ORLANDO, Fla. (Ivanhoe Newswire) - The American Cancer Society reports that about one in eight men will be diagnosed with prostate cancer in their lifetime. The average age of men who get diagnosed is ...
Only men with a dangerous genetic variant and a family history of cancer should be offered screening, say UK advisors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results